查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362945

北美尿道感染检测（UTI 检测）市场规模、份额和趋势分析报告：2023-2030 年按类型、按产品、最终用途、国家和细分市场分類的趋势

North America Urinary Tract Infection Testing Market Size, Share & Trends Analysis Report By Type, By Product, By End-use, By Country, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

北美尿道感染检测（UTI检测）市场成长与趋势：

Grand View Research, Inc. 的一项新研究显示，到 2030 年，北美 UTI 检测市场规模预计将达到 2.6916 亿美元。

预计 2023 年至 2030 年该市场将以 4.0% 的年复合成长率扩张。由于该地区政府控制泌尿道感染的倡议不断增加、尿路感染检测技术的进步以及高度发达的医疗基础设施和医疗设施的普及，该地区尿路感染检测市场正在不断增长。例如，根据《纽约时报》2019 年 7 月发表的报导，纽约市卫生部推出了一款对抗抗药性泌尿道感染的行动应用程式。该应用程式为医生和护士提供了感染菌株和对某些药物的抗药性的清单。

卫生部进行的研究表明，许多由大肠桿菌（最常见的类型）引起的尿道结石对广泛使用的药物（例如 Bactrim）具有抗药性。人们对抗药性尿道结石的日益关注正在推动北美地区对先进尿路感染检测解决方案的需求。医疗保健提供者正在寻求更精确、更有针对性的治疗方法，以应对日益严重的抗生素抗药性问题。因此，该地区的尿路感染检测市场正在经历显着成长。

结合创新诊断技术可以显着增强患者照护和管理，同时透过更快的结果交付促进抗生素管理，推动市场成长。例如，由美国工程师和分子生物学家组成的团队开发了一种具有成本效益的即时诊断测试，可以快速检测尿液中的微生物病原体。该设备使用简单的实验室套件、LED 灯、热板和智慧型手机，在资源有限的环境中显示出快速、低成本诊断尿路感染的巨大潜力。

北美尿路感染检测市场报告亮点

  • 整体市场的成长归因于该地区人口中尿路感染的患病不断上升。
  • 随着对技术先进的居家照护道感染检测套组的需求不断增加，泌尿道感染检测市场正在发生重大变化。
  • 由于膀胱炎患者的发生率和復发率较高，2022年膀胱炎占最大的市场占有率，为41.41%。
  • 设备部门市场占据主导地位，2022年销售份额为60.36%。这是因为诊断技术的进步促进了功能增强的先进设备的开发。
  • 以最终用途，参考实验室领域在 2022 年占据最大销售份额，达到 26.11%。这是由于这些实验室提供了广泛的综合测试服务。

目录

第1章调查方法与范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19感染疾病的影响分析

第4章北美UTI检测市场：类型分析

  • 北美UTI测试市场：类型变异分析
  • 尿道炎
  • 膀胱炎
  • 肾盂肾炎

第5章北美UTI检测市场：产品分析

  • 北美UTI测试市场：产品变化分析
  • 装置
  • 消耗品

第6章北美 UTI 测试市场：最终用途分析

  • 北美 UTI 测试市场：最终用途变化分析
  • 全科医生
  • 泌尿系统
  • 泌尿妇科医生
  • 医院实验室
  • 参考实验室
  • 医院急诊部门
  • 紧急护理
  • 其他的

第7章北美UTI检测市场：区域分析

  • 北美洲

第8章竞争形势

  • 参与企业
    • QIAGEN
    • Accelerate Diagnostics, Inc.
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Danaher Corporation
    • Siemens Healthcare GmbH
    • Randox Laboratories Ltd.
    • Thermo Fisher Scientific, Inc.
    • bioMerieux SA
    • T2 Biosystems, Inc.
  • 参与企业概况
  • 财务实绩
  • 产品基准评效
  • 2022 年公司市场占有率分析
  • 策略规划
    • 扩张
    • 收购
    • 产品/服务发布
    • 其他的

第9章结论/分析师的观点

Product Code: GVR-4-68040-113-0

North America Urinary Tract Infection Testing Market Growth & Trends:

The North America urinary tract infection testing market size is expected to reach USD 269.16 million by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 4.0% from 2023 to 2030. The regional UTI testing market is growing due to increasing government initiatives regarding UTI control in the region, technological advancements in UTI testing, and highly developed healthcare infrastructure & improved access to healthcare facilities. For instance, an article published by The New York Times in July 2019 mentioned that the New York City Department of Health launched a mobile app to address drug-resistant urinary tract infections (UTIs). The app provides doctors and nurses with a list of infection strains and their resistance to specific drugs.

Research conducted by this department revealed that many of the UTIs caused by E. coli, the most common type, were resistant to widely used drugs like Bactrim. This growing concern over drug-resistant UTIs drives the demand for advanced UTI testing solutions in North America, as healthcare providers seek more accurate and targeted therapies to combat the rising issue of antibiotic resistance. As a result, the UTI testing market in the region is experiencing significant growth.

Incorporating innovative diagnostic technologies can significantly enhance patient care and management while promoting antibiotic stewardship through faster result delivery, thereby driving market growth. For instance, a team of engineers and molecular biologists in the U.S. has developed a cost-effective point-of-care diagnostic test for rapidly detecting microbial pathogens in urine. Using a simple lab kit, LED lights, a hot plate, and a smartphone, the device shows promising potential for quick and low-cost diagnosis of urinary tract infections (UTIs) in resource-limited settings.

Furthermore, a pilot study published in eBioMedicine compared the smartphone-based real-time loop-mediated isothermal amplification (smaRT-LAMP) system to the more expensive rapid diagnostic technologies and standard hospital tests. The results demonstrated that the smaRT-LAMP system matched the accuracy of hospital diagnostics while significantly reducing costs and testing time.

Key players in the regional urinary tract infection testing market, such as F. Hoffmann-La Roche Ltd., bioMerieux SA, T2 Biosystems, Abbott, Siemens Healthcare GmbH, etc., are implementing strategic initiatives such as mergers, acquisitions, and collaborations to enhance product capabilities and promote their offerings. For instance, in November 2022, Illumina, a global leader in DNA sequencing and array-based technologies, introduced the Illumina Urinary Pathogen Infectious Disease/Antimicrobial Resistance (ID/AMR) Panel (UPIP). This research test utilizes precision metagenomics to identify and measure genitourinary pathogens, including drug-resistant ones that lead to complicated and recurrent urinary tract infections (UTIs).

North America Urinary Tract Infection Testing Market Report Highlights:

  • The growth of the overall market is attributed to the increasing prevalence of UTIs among the population in the region
  • The UTI testing market is witnessing a key shift with the rise in demand for technologically advanced homecare UTI testing kits
  • Cystitis held the largest market share of 41.41% in 2022, owing to the high incidence & recurrence rate of cystitis in patients
  • The instruments segment dominated the market with a revenue share of 60.36% in 2022. This is attributed to advancements in diagnostic technologies that have led to the development of sophisticated instruments with enhanced capabilities
  • Based on end-use, the reference laboratories segment accounted for the largest revenue share of 26.11% in 2022. This is attributed to the wide range of comprehensive testing services offered by these laboratories

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type segment
      • 1.1.1.2. Product segment
      • 1.1.1.3. End-user segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Product and Type Snapshot
  • 2.3. End-use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of urinary tract infections (UTIs)
      • 3.2.1.2. Technological Advancements in Urinary Tract Infection Testing
      • 3.2.1.3. Growing prevalence of catheter-associated UTIs (CAUTIs)
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost associated with advanced UTI testing technologies.
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. North America Urinary Tract Infection Testing Market: Type Analysis

  • 4.1. North America Urinary Tract Infection Testing Market: Type Movement Analysis
  • 4.2. Urethritis
    • 4.2.1. Urethritis Market, 2018 - 2030 (USD Million)
  • 4.3. Cystitis
    • 4.3.1. Cystitis Market, 2018 - 2030 (USD Million)
  • 4.4. Pyelonephritis
    • 4.4.1. Pyelonephritis Market, 2018 - 2030 (USD Million)

Chapter 5. North America Urinary Tract Infection Testing Market: Product Analysis

  • 5.1. North America Urinary Tract Infection Testing Market: Product Movement Analysis
  • 5.2. Instruments
    • 5.2.1. Instruments Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 5.3. Consumables
    • 5.3.1. Consumables Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

Chapter 6. North America Urinary Tract Infection Testing Market: End-use Analysis

  • 6.1. North America Urinary Tract Infection Testing Market: End-use Movement Analysis
  • 6.2. General Practitioners
    • 6.2.1. General Practitioners Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.3. Urologists
    • 6.3.1. Urologists Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.4. Urogynecologists
    • 6.4.1. Urogynecologists Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.5. Hospital Laboratories
    • 6.5.1. Hospital Laboratories Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.6. Reference Laboratories
    • 6.6.1. Reference Laboratories Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.7. Hospital Emergency Departments
    • 6.7.1. Hospital Emergency Departments Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.8. Urgent Care
    • 6.8.1. Urgent Care Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6.9. Others
    • 6.9.1. Others Market, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

Chapter 7. North America Urinary Tract Infection Testing Market: Regional Analysis

  • 7.1. North America
    • 7.1.1. SWOT Analysis
    • 7.1.2. North America Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)
    • 7.1.3. U.S.
      • 7.1.3.1. Key Country Dynamics
      • 7.1.3.2. Target Disease Prevalence
      • 7.1.3.3. Competitive Scenario
      • 7.1.3.4. Regulatory Framework
      • 7.1.3.5. U.S. Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)
    • 7.1.4. Canada
      • 7.1.4.1. Key Country Dynamics
      • 7.1.4.2. Target Disease Prevalence
      • 7.1.4.3. Competitive Scenario
      • 7.1.4.4. Regulatory Framework
      • 7.1.4.5. Canada Urinary Tract Infection Testing Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
    • 8.1.1. QIAGEN
      • 8.1.1.1. Overview
      • 8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.1.3. Product Benchmarking
      • 8.1.1.4. Strategic Initiatives
    • 8.1.2. Accelerate Diagnostics, Inc.
      • 8.1.2.1. Overview
      • 8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.2.3. Product Benchmarking
      • 8.1.2.4. Strategic Initiatives
    • 8.1.3. Bio-Rad Laboratories, Inc.
      • 8.1.3.1. Overview
      • 8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.3.3. Product Benchmarking
      • 8.1.3.4. Strategic Initiatives
    • 8.1.4. F. Hoffmann-La Roche Ltd.
      • 8.1.4.1. Overview
      • 8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.4.3. Product Benchmarking
      • 8.1.4.4. Strategic Initiatives
    • 8.1.5. Danaher Corporation
      • 8.1.5.1. Overview
      • 8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.5.3. Product Benchmarking
      • 8.1.5.4. Strategic Initiatives
    • 8.1.6. Siemens Healthcare GmbH
      • 8.1.6.1. Overview
      • 8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.6.3. Product Benchmarking
      • 8.1.6.4. Strategic Initiatives
    • 8.1.7. Randox Laboratories Ltd.
      • 8.1.7.1. Overview
      • 8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.7.3. Product Benchmarking
      • 8.1.7.4. Strategic Initiatives
    • 8.1.8. Thermo Fisher Scientific, Inc.
      • 8.1.8.1. Overview
      • 8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.8.3. Product Benchmarking
      • 8.1.8.4. Strategic Initiatives
    • 8.1.9. bioMerieux SA
      • 8.1.9.1. Overview
      • 8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.9.3. Product Benchmarking
      • 8.1.9.4. Strategic Initiatives
    • 8.1.10. T2 Biosystems, Inc.
      • 8.1.10.1. Overview
      • 8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.10.3. Product Benchmarking
      • 8.1.10.4. Strategic Initiatives
  • 8.2. Participant's Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Company Market Share Analysis, 2022
  • 8.6. Strategy Mapping
    • 8.6.1. Expansions
    • 8.6.2. Acquisitions
    • 8.6.3. Product/Service Launches
    • 8.6.4. Others

Chapter 9. Conclusion/Analyst Perspective

List of Tables

  • 1. List of Secondary Sources
  • 2. List of Abbreviations
  • 3. North America Urinary Tract Infection Testing Market, By Country, 2018 - 2030 (USD Million)
  • 4. North America Urinary Tract Infection Testing Market, By Type, 2018 - 2030 (USD Million)
  • 5. North America Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 6. North America Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 7. U.S. Urinary Tract Infection Testing Market, by Type, 2018 - 2030 (USD Million)
  • 8. U.S. Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 9. U.S. Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 10. Canada Urinary Tract Infection Testing Market, by Type, 2018 - 2030 (USD Million)
  • 11. Canada Urinary Tract Infection Testing Market, By Product, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 12. Canada Urinary Tract Infection Testing Market, by End - use, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)

List of Figures

  • 1. Market research process
  • 2. Information procurement
  • 3. Primary research pattern
  • 4. Market research approaches
  • 5. Value chain - based sizing & forecasting
  • 6. Market formulation & validation
  • 7. North America urinary tract infection testing: Market segmentation
  • 8. Market snapshot, 2022
  • 9. Market Trends & Outlook
  • 10. Market driver relevance analysis (current & future impact)
  • 11. Market restraint relevance analysis (current & future impact)
  • 12. Market challenge relevance analysis (current & future impact)
  • 13. SWOT analysis
  • 14. Porter's five forces analysis
  • 15. North America urinary tract infection testing market: Type outlook and key takeaways
  • 16. North America urinary tract infection testing market: Type movement analysis & market share, 2022 & 2030
  • 17. Urethritis market estimates and forecast, 2018 - 2030 (USD Million)
  • 18. Cystitis market estimates and forecast, 2018 - 2030 (USD Million)
  • 19. Pyelonephritis market estimates and forecast, 2018 - 2030 (USD Million)
  • 20. North America urinary tract infection testing market: Product outlook and key takeaways
  • 21. North America urinary tract infection testing market: Product movement analysis & market share, 2022 & 2030
  • 22. Instruments market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 23. Consumables market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 24. North America urinary tract infection testing market: End - use outlook and key takeaways
  • 25. North America urinary tract infection testing market: End - use movement analysis & market share, 2022 & 2030
  • 26. General practitioners market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 27. Urologists market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 28. Urogynecologists market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 29. Hospital laboratories market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 30. Reference laboratories market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 31. Hospital emergency departments market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 32. Urgent care market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 33. Others market estimates and forecast, 2018 - 2030 (Revenue, USD Million; Volume, Units, 2018 - 2030)
  • 34. Regional marketplace: key takeaways
  • 35. Regional outlook, 2022 & 2030
  • 36. North America urinary tract infection testing market: region movement analysis.
  • 37. North America urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)
  • 38. U.S. key country dynamics
  • 39. U.S. urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)
  • 40. Canada key country dynamics
  • 41. Canada urinary tract infection testing market, 2018 - 2030 (Revenue, USD Million, 2018 - 2030)